Our team

ASC Therapeutics is an independent, fully incorporated biopharmaceutical company with dedicated scientists and industry veterans with a strong belief in gene and cell therapy, the future for treating rare disease.

The company leverages over 12 years of experience by Applied StemCell, Inc., a separate entity, focused on developing and improving gene editing and stem cell technologies.

Executive Team

Ruhong Jiang, PhD

Co-founder, President and CEO

-20+ years industrial experience (US and China) in research tool, molecular diagnostic product and drug development, and corporate development

-General manager of MicuRx, China

-Founding members of two biotech companies

-Co-founder of two biotech companies

Oscar Segurado, MD, PhD

Chief Medical Officer

-20+ years pre-clinical, clinical & regulatory experience, including gene therapy at AveXis and uniQure

-Responsible for Humira clinical development and 2007 US Patent at AbbVie

-Tenured Professor of Immunology with 100+ peer-reviewed publications

Allan L. Shaw

Chief Financial Officer

-20+ years in domestic & international financial transactions

-Closed 11 business development deals (e.g. GSK, Amgen, J&J), up to $600M deal size each transaction

-Closed 11 equity transactions in US ad EU markets

Gary Potter Headshot

Gary Potter


– 20+ years of GMP manufacturing experience in gene therapies, cell culture manufacturing and whole cell anti-cancer therapies

–Facility design, start-up, engineering, validation, and operations

-Global manufacturing facilities in the US and Europe at uniQure

Steve Zhang, PhD

VP, Gene & Cell Therapy

-20 years of biotech experience developing novel technologies and genetic therapies

-Former associate director at Sangamo Therapeutics

-Inventor of multiple patents in the field of gene therapy, gene regulation and genome editing

-Ph.D. in molecular genetics from Washington University

Zoya Gluzman-Poltorak, PhD, MBA

VP, Therapeutic Development

-Over 20 years of executive-level leadership experience, advancing cell, gene and protein therapies from idea through pre-clinical and clinical development in multiple therapeutic areas (Hematology, Immunology, Oncology, Neurology, Dermatology, and Cardiovascular Diseases).

-Former Senior Director of Development and Head of Immuno-Oncology at Neumedicines Inc., Pasadena, CA.

-Former Chief Technology Officer at Gene Grafts Ltd. and Angiogenesis Project Lead at MGVS Ltd., Haifa, Israel.

-Cell and Gene  Therapy Consultant and Biforum, Israel.

-PhD in Cell and Molecular Biology and MBA from the Technion, Israel Institute of Technology, Haifa, Israel.

-Co-author of multiple patents and peer-reviewed publications.

Weicheng Wu, PhD, RAC


– 20+ years of experience in biomedical research and regulatory affairs (US, EU, Canada, China)

– Broad regulatory experience supporting development and commercialization of biologics, drugs, molecular diagnostics and medical devices

– Successfully submitted several INDs/CTAs for new biologics and drugs

Lijing Li

Senior Director, CMC  Cell and Gene therapy

-More than 25 years’ experience in research and therapeutics development.

-Proven success in setting up translational medicine platform to bring research into clinic.

-Extensive experience in research, preclinical study, process development, GMP manufacturing, analytical development, and quality control.

-10+ years industrial experience in drug development for gene and cell therapy including autologous and allogeneic CarT and Hematopoietic Stem Cell engineering with lentiviral vector, AAV vector, adenoviral vector, and Zinc Finger Nuclease.